Talisay Jr, Eusebio F.

HRN: 29-34-19  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/23/2026
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
07/23/2026
07/30/2026
IV
2.25mg
Q6
CAP MR; CELLULITIS
Pending Pharmacy Acceptance 

 Indication:  Empiric    Type of Infection:  PneumoniaSkin & Soft Tissue    Compliance to guidelines: